Quanterix Corporation (QTRX)
US — Healthcare Sector
Automate Your Wheel Strategy on QTRX
With Tiblio's Option Bot, you can configure your own wheel strategy including QTRX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol QTRX
- Rev/Share 2.8003
- Book/Share 6.8288
- PB 0.8303
- Debt/Equity 0.1276
- CurrentRatio 3.0158
- ROIC -0.2913
- MktCap 264850219.0
- FreeCF/Share -1.481
- PFCF -3.8825
- PE -2.73
- Debt/Assets 0.0903
- DivYield 0
- ROE -0.3053
- Rating B-
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 5
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | QTRX | Canaccord Genuity | Buy | Hold | -- | $5 | Aug. 11, 2025 |
News
The Schall Law Firm Invites Shareholders With Losses In Quanterix Corporation To Join A Securities Fraud Investigation
QTRX
Published: February 10, 2025 by: Accesswire
Sentiment: Neutral
Published: February 10, 2025 by: Accesswire
Sentiment: Neutral
LOS ANGELES, CA / ACCESS Newswire / February 10, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Quanterix Corporation ("Quanterix" or "the Company") (NASDAQ:QTRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Read More
About Quanterix Corporation (QTRX)
- IPO Date 2017-12-07
- Website https://www.quanterix.com
- Industry Medical - Devices
- CEO Everett V. Cunningham
- Employees 471
Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. It offers HD-X instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids. The company also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assay kits and other consumables such as reagents. In addition, it offers contract research services, including sample testing, homebrew assay development, and custom development services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct sales force, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.